Goldfinch Bio, a US biotech developing precision medicines for kidney diseases, has agreed a licensing deal giving it global rights to a cannabinoid receptor 1 (CB1) monoclonal antibody from Japanese pharma major Takeda (TYO: 4502).
This allows Goldfinch Bio to assume all development and commercialization responsibilities for the drug in the treatment of rare and metabolic kidney diseases worldwide.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze